lazertinib,amivantamab
yuhan corp,oscotec,janssen,genmab
['lung', 'lazertinib']
today at 2:00 pm edt, catherine shu, md, ( ) will share updates from a study of amivantamab and lazertinib in patients with egfr-mutant non-small cell lung cancer, which has demonstrated encouraging antitumor activity. more info: 
Updates on innovations in #cancer research, prevention, care, and education from the Herbert Irving Comprehensive Cancer Center at @columbiamed/@nyphospital.